Navigation Links
PolyOne Announces Third Quarter 2011 Results
Date:10/25/2011

CLEVELAND, Oct. 25, 2011 /PRNewswire-FirstCall/ --

  • Revenues increase 8% versus third quarter 2010
  • Diluted earnings per share of $0.23 versus $0.04 in the prior-year third quarter
  • Adjusted earnings per share expand 10% over third quarter 2010 to $0.26 per share
  • Agreements to acquire ColorMatrix and establish joint venture in Middle East to drive specialty growth

  • PolyOne Corporation (NYSE: POL) today reported revenues of $735.8 million for the third quarter of 2011, an 8% increase compared to revenues of $680.8 million in the third quarter of 2010.  

    Diluted earnings per share totaled $0.23 in the third quarter of 2011, compared to $0.04 per diluted share in the third quarter of 2010.  Adjusted earnings per share increased 10% to $0.26 for the third quarter of 2011 up from $0.24 recorded in the third quarter last year.

    "I am pleased that we expanded year over year earnings per share despite a number of headwinds," said Stephen D. Newlin, chairman, president and chief executive officer.  "During the third quarter, we observed slower global economic growth, a weaker euro, increased competitive pressure in our Performance Products and Solutions segment and higher taxes."

    "We expect these challenges could remain for the near term, but we are very optimistic our performance will continue to improve over the mid to long term, as we continue shifting our mix toward higher margin, more specialized products and services," added Newlin.  "Our announced agreements to acquire ColorMatrix and form a joint venture in Saudi Arabia illustrate perfectly our strategy of adding new technologies and expanding our presence in high-growth markets and geographies."

    "Our strong track record of converting earnings to cash continues as we generated $20 million of free cash flow while also accelerating capital expenditu
    '/>"/>

    SOURCE PolyOne Corporation
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

    Related medicine technology :

    1. PolyOne GLS Selected as Healthcare Industry Marketing Specialist for Santoprene™ TPV Medical Grades
    2. PolyOne Announces Sale of SunBelt Investment
    3. PolyOne Features Non-Lead Radiation Protection at Medical Design and Manufacturing East Exhibition
    4. PolyOnes Healthcare Solutions and Distribution Network Showcased at Medtec China
    5. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
    6. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
    7. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
    8. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
    9. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
    10. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
    11. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:7/27/2015)... -- The fairness of the proposed acquisition of Thoratec Corporation ... Jude") is the subject of an investigation by WeissLaw ...  The investigation is focusing on possible breaches of fiduciary ... of Directors of THOR for agreeing to sell the ... announced it had reached a definitive agreement for St. ...
    (Date:7/27/2015)... , July 20, 2015 ... has announced the addition of the "Cardiometabolic ... Afrezza,s discounted pricing is in line ... is critical to the product,s commercial appeal. However, ... prevent Afrezza from gaining a sizeable share of ...
    (Date:7/27/2015)...  Attorney Advertising-- Bronstein, Gewirtz & Grossman, LLC is ... the securities of AMAG Pharmaceuticals Inc. ("AMAG" or ... advised to contact Peretz Bronstein or ... at info@bgandg.com or 212-697-6484. ... its officers and/or directors have violated Sections 10(b) ...
    Breaking Medicine Technology:WeissLaw LLP: Thoratec Corporation Acquisition By St. Jude Medical May Not Be In The Best Interest Of THOR Shareholders 2Cardiometabolic Drug News Issue - Afrezza Aggressive Pricing Strategy View Playing Out 2Cardiometabolic Drug News Issue - Afrezza Aggressive Pricing Strategy View Playing Out 3SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of AMAG Pharmaceuticals Inc. 2
    ... PRINCETON, N.J. , June 21 Celator Pharmaceuticals today ... (Nasdaq: CEPH). The research agreement provides for the utilization of Celator,s ... at Cephalon. , , ... "We are pleased that work with this research program has ...
    ... June 21 U.S. District Court Judge Sidney A. Fitzwater ... class action lawsuit that left hundreds of premature babies with life threatening medical ... Canada will receive compensation under the settlement. , ... "It took years of litigation and research to pry relevant information ...
    Cached Medicine Technology:Celator® Pharmaceuticals Expands Research Agreement With Cephalon, Inc. 2Celator® Pharmaceuticals Expands Research Agreement With Cephalon, Inc. 3Fort Worth Attorney Dwain Dent Comments on Final Judgment in Case That Left Hundreds of Babies Dead or Injured 2
    (Date:7/27/2015)... (PRWEB) , ... July 27, 2015 , ... Eugene Batelli, ... an accomplished athlete. “The patient is high-end athlete, whose accomplishments include running in ... months of Achilles tendon pain, which was diagnosed as tendinitis. I did an ...
    (Date:7/27/2015)... ... 27, 2015 , ... The Maricopa Community Colleges today announced a ... system to get into and complete college. , The “Bridging Success Initiative,” funded ... today with partners from across the valley. , The initiative advisory board has representatives ...
    (Date:7/27/2015)... ... July 27, 2015 , ... David Gilmour ... will be performing for one additional night at each of his original four tour ... for added savings. , David Gilmour’s 2016 North America tour dates: , Thursday, March ...
    (Date:7/27/2015)... (PRWEB) , ... July 27, ... ... on Global Calcium Propionate industry is a professional and in-depth research report. ... overview, industry chain structure, international market analysis etc. This report covers the ...
    (Date:7/27/2015)... Chico, CA (PRWEB) , ... July 27, 2015 , ... ... has teamed up with PursuitSAFETY to support its mission of reducing the number of ... funds to help support victims and their families. PursuitSAFETY works with the police ...
    Breaking Medicine News(10 mins):Health News:NJ Top Docs Presents, Dr. Eugene Batelli of Metropolitan Ankle & Foot Care Specialists 2Health News:NJ Top Docs Presents, Dr. Eugene Batelli of Metropolitan Ankle & Foot Care Specialists 3Health News:Maricopa Community Colleges Launch Program To Help Youth In Foster Care Finish College 2Health News:Maricopa Community Colleges Launch Program To Help Youth In Foster Care Finish College 3Health News:Cheap David Gilmour Tickets at Madison Square Garden (MSG), Air Canada Center, United Center and Hollywood Bowl: Additional Dates for David Gilmour Go On Sale Today 2Health News:Calcium Propionate Market Global Suppliers and Manufacture Analysis 2Health News:Calcium Propionate Market Global Suppliers and Manufacture Analysis 3Health News:Gary Short & Associates in Chico, CA Initiates Charity Campaign to Collaborate with National Nonprofit PursuitSAFETY 2Health News:Gary Short & Associates in Chico, CA Initiates Charity Campaign to Collaborate with National Nonprofit PursuitSAFETY 3
    ... Phase II for melanoma, to begin Phase II for breast ... cancer ... today at 9:00 a.m. EDT -, BRANFORD, Conn., April 22 CuraGen Corporation,(Nasdaq: ... the quarter ended March 31, 2008, CuraGen reported a net loss,of $6.8 million, or ...
    ... China, April 22 /Xinhua-PRNewswire Simcere Pharmaceutical,Group (NYSE: ... of,branded generic pharmaceuticals and manufacturer of the ... announced that it has,signed a definitive agreement ... Wuhu,Zhong Ren Pharmaceutical Co. Ltd. for a ...
    ... for the Service,Employees International Union claimed in an ... other acts of intimidation against,officers, directors and staff ... nothing more than "free speech.", A temporary ... Court Commission Jon Rantzman remains in effect today. ...
    ... treatment with drug 5-fluorouracil, study says , , MONDAY, April ... used chemotherapy drug causes memory problems and other cognitive ... brain," a new study found. , Up to 50 ... problems a year after chemotherapy treatment ended, according to ...
    ... DANVILLE, PA. Hearing repeated stories of suffering from ... workers, a new Geisinger-led study suggests. , In a ... Social Work Practice, Geisinger Senior Investigator Joseph Boscarino, PhD, ... and secondary trauma among 236 New York City social ...
    ... Appointed to Board ... of Directors, CINCINNATI, April 21, 2008 ... (Jack) F. Smith (70),will retire from the board following P&G,s April board meeting ... to:, http://www.prnewswire.com/mnr/pg/32757/ Mr. Smith has served on the board since 1995 ...
    Cached Medicine News:Health News:CuraGen Reports First Quarter 2008 Financial Results 2Health News:CuraGen Reports First Quarter 2008 Financial Results 3Health News:CuraGen Reports First Quarter 2008 Financial Results 4Health News:CuraGen Reports First Quarter 2008 Financial Results 5Health News:CuraGen Reports First Quarter 2008 Financial Results 6Health News:Simcere Pharmaceutical Group Acquires 70% Stake in Wuhu Zhong Ren Pharmaceutical Co. Ltd. 2Health News:SEIU Claims Right of 'Free Speech' to Stalk, Harass, and Threaten Registered Nurses According to the California Nurses Association 2Health News:Common Chemotherapy Drug Linked to Memory Problems 2Health News:Common Chemotherapy Drug Linked to Memory Problems 3Health News:Procter & Gamble Announces Board Changes 2
    The Shandon Cryotome E Cryostat model features an automated, precise electronic specimen advance system....
    The Shandon Pathcentre is a high-volume, totally enclosed tissue processor that allows complete user control and excellent continuous reagent agitation....
    ... Shandon Excelsior Tissue Processor is ... using traditional reagents today. It ... outstanding features to provide benefits ... increased productivity, reagent cost savings ...
    The Shandon Grosslab Grossing Workstation comes in a bench top or stand alone design for the gross examination and sectioning of specimens....
    Medicine Products: